What Is the Scope and Claim Coverage of US Patent 8,865,688?
US Drug Patent 8,865,688 is directed to a method for maintaining remission of ulcerative colitis using a specific granulated mesalamine once-daily regimen with defined release, food, and concomitant-administration constraints, and with quantified delivery to the terminal ileum and colon. The independent claim is tightly framed around a clinical outcome (DAI 0 or 1 at 6 months) plus multiple formulation and use conditions, which constrains both literal infringement and most design-around paths.
Core claim elements (independent claim 1)
Claim 1 requires all of the following in combination:
-
Indication and endpoint
- Ulcerative colitis remission maintenance in a subject
- Remission is defined as DAI score 0 or 1
- Therapy maintains remission for at least 6 months
-
Product form and dosing geometry
- Granulated mesalamine formulation
- Four capsules per dose
- Each capsule contains 0.375 g granulated mesalamine
- Total daily dose = 4 × 0.375 g = 1.5 g once per day
- Dosed in the morning
- Dosed “without food” (express condition)
-
Concomitant administration limitation
- Formulation is not administered with antacids
-
Exposure to target segments
- 85% to 90% of mesalamine reaches the terminal ileum and colon
Those requirements make the claim more like a “use of a specific sustained-release product under specific instructions” than a broad method of mesalamine therapy.
What Do the Dependent Claims Add?
Claim dependency map
- Claim 1: Independent method
- Claim 2-3: Define release characteristics
- Claim 4: Age group
- Claims 5-13: Safety-advice and interaction/warnings (mostly conditional advice plus renal/CYP/antacids related statements already partly present)
- Claims 14-15: Patient selection and release timing approximation
- Claims 16: Duplicates claim 1 as another independent-style method claim (same core constraints)
Product-release specifics
- Claim 2: “Delayed and extended release” formulation.
- Claim 3: Release profile includes:
- first releasing mesalamine in the ileum
- continuing to release mesalamine through the terminal ileum and colon
- Claim 15: Mesalamine is released over approximately 7 hours.
These dependent claims narrow coverage to a specific type of intestinal release pattern and implicitly require that the accused product’s release kinetics and regional delivery match.
Patient population constraint
- Claim 4: Applies to maintenance of remission in subjects 18 years and older.
Safety and instruction content (labeling-style method elements)
- Claim 5: Advise hypersensitivity subjects (salicylates/aminosalicylates/components) not to receive.
- Claims 6-7: Renal impairment may occur; assess renal function:
- beginning/before therapy and/or
- periodically during therapy.
- Claim 8: Advise acute exacerbation can occur.
- Claims 9: Use caution in renal disease.
- Claim 10: Monitor blood cell counts in geriatric subjects.
- Claims 11-12: Advise adverse reactions; list includes:
- headache
- diarrhea
- upper abdominal pain
- nausea
- nasopharyngitis
- flu or flu-like illness
- sinusitis
- Claim 13: Advise product does not inhibit metabolism of drugs that are substrates of:
- CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4
Patient selection element
- Claim 14: Selecting a subject with DAI 0 or 1 for maintaining remission with granulated mesalamine.
Claim 16
Claim 16 repeats the essential “method” elements of claim 1:
- granulated mesalamine not taken with antacids
- 4 capsules × 0.375 g once daily in the morning without food
- maintain remission ≥6 months
- DAI 0 or 1
- 85% to 90% reaches terminal ileum and colon
Where the Claim Draws the “Infringement Fence”
1) The regimen constraints are conjunctive
Infringement requires matching all major conditions in claim 1 (and in relevant dependent claims). The fence is built from:
- Dose geometry: 1.5 g/day delivered as four 0.375 g capsules
- Timing/administration: morning and without food
- Concomitant: not administered with antacids
- Target delivery: 85% to 90% reaches terminal ileum and colon
- Outcome: remission maintained for ≥ 6 months, with remission defined as DAI 0 or 1
A generic mesalamine maintenance regimen that differs on any one of these axes risks falling outside literal claim scope.
2) “Without food” and “not with antacids” are operational limits
These instructions are not just clinical preferences; they are claim limitations. A product labeled for use “with or without food,” or that is used in combination protocols with antacids, can become a non-infringing use case depending on how “administered” is proven in enforcement.
3) The delivery fraction (85% to 90%) is a numeric, testable element
This is a key narrowing feature. The claim requires a mesalamine product where the delivery to terminal ileum and colon is between 85% and 90%. That creates a measurable infringement axis tied to formulation and/or in vivo delivery performance.
4) Release kinetics narrows to “delayed and extended,” with ileum-first release
Claims 2 and 3 require:
- delayed and extended release
- first release in ileum
- continued release through terminal ileum and colon
Claim 15 adds a time basis: ~7-hour release.
5) DAI-based outcome anchors the method
Claim 1 defines remission (DAI 0 or 1) and requires maintenance for at least 6 months. That shapes enforcement to controlled/monitored use patterns rather than short-term dosing.
What Is the Practical Infringement Scope?
Literal coverage likely includes
- Once-daily maintenance therapies using granulated mesalamine that match:
- 1.5 g total daily dose via four 0.375 g capsules
- morning administration without food
- avoidance of antacids
- intestinal delivery where 85% to 90% reaches the terminal ileum and colon
- delayed/extended release with ileum-first release and continuation into the colon
- release duration around 7 hours
- Use for adults ≥18, and with labeling/instructions consistent with the dependent claims (if the asserted claim set includes those dependent elements).
Key “likely non-coverage” lanes
- Products that are not granulated mesalamine (if “granulated” is essential to the definition).
- Formulations with different dosing geometry:
- different capsule count or per-capsule dose
- different total daily dose
- Regimens that allow dosing with food
- Protocols permitting co-administration with antacids
- Products with delivery outside the 85% to 90% terminal ileum/colon target (more/less fraction)
- Release profiles that are not ileum-first delayed and extended release, or not ~7 hours
Patent Landscape: How 8,865,688 Fits in the US Mesalamine “Maintenance” Space
Claim style indicates a formulation-administration program, not a broad class method
This patent’s structure mirrors a strategy common in oral 5-ASA intellectual property: lock coverage onto:
- a specific oral form (granulated, with delayed/extended release behavior),
- a specific dose architecture (4 × 0.375 g),
- dosing timing and administration rules (“morning,” “without food,” “no antacids”),
- quantified segment delivery (85% to 90% terminal ileum and colon),
- and a clinical endpoint (DAI 0 or 1 for ≥6 months).
High-risk adjacent variants
A competitor attempting to launch a “near match” would face two main technical risk points:
- Delivery fraction and regional distribution (85% to 90% target)
- Release timing and ileum-first behavior (~7-hour release; first release in ileum; continuing through terminal ileum and colon)
Changes that adjust one dimension (such as dose timing) without addressing the delivery fraction and release pattern are still vulnerable if other elements match and enforcement can prove the claimed use conditions.
Design-around pressure points
Practical design-around levers implied by claim architecture:
- Alter dosing instructions so that use is not “without food” or not “not administered with antacids” in typical label-driven use.
- Reformulate to shift delivery fraction outside 85% to 90% for terminal ileum/colon.
- Change release kinetics so it does not meet “delayed and extended,” “first releasing in ileum,” or “approximately 7 hours.”
- Use a different dosage architecture (not four capsules each 0.375 g) or different total daily mg regimen.
Because the claims are conjunctive, a single successful deviation on any one of the above axes can move a product out of literal scope.
Freedom-to-Operate Read: What Matters Most for Assessment
Elements to test in FTO diligence
For any candidate product or protocol, the highest-value technical and regulatory questions are:
- Does it use “granulated mesalamine”?
- Is dosing exactly four capsules of 0.375 g each (1.5 g once daily)
- Is administration “in the morning” and “without food”
- Does the label or real-world use include “not with antacids”
- Does delivery meet 85% to 90% mesalamine reaching terminal ileum and colon
- Does the release profile match the dependent limitations
- delayed and extended release
- ileum-first release and continuation through terminal ileum/colon
- approximately 7-hour release duration
- Does the claimed use context align with remission maintenance
- DAI 0 or 1
- maintained for at least 6 months
- Age and safety-advice scope (only if the asserted claim includes those dependent steps)
Evidence sources that typically matter for enforcement
- In vivo delivery/distribution studies supporting the 85% to 90% terminal ileum/colon fraction
- Dissolution/release characterization for ~7-hour delayed/extended ileum-first release
- PK/food-effect data supporting “without food”
- Labeling instructions supporting “not with antacids”
- Clinical maintenance trial evidence defining DAI remission and duration
Key Takeaways
- US 8,865,688 is a narrow, conjunctive method patent anchored on remission maintenance (DAI 0 or 1 for ≥6 months) plus a specific granulated mesalamine once-daily regimen (four capsules of 0.375 g, morning, without food).
- Two product-performance limits dominate risk: (a) 85% to 90% mesalamine reaching terminal ileum and colon and (b) delayed/extended release with ileum-first release and ~7-hour release duration.
- Use-instructions are claim limitations: “not administered with antacids” and “without food” constrain potential infringement and shape design-around strategy.
- Dependent claims add adult age (≥18) plus safety/labeling-style steps (renal monitoring, hypersensitivity warnings, adverse reactions list, and CYP substrate metabolism non-inhibition statement).
FAQs
1) What is the total daily mesalamine dose in US 8,865,688?
1.5 g per day, administered as four capsules of 0.375 g each once daily.
2) What clinical definition of remission does the patent require?
Remission is defined as DAI score of 0 or 1.
3) How long must remission be maintained under the independent claim?
For a period of at least 6 months of treatment.
4) What is the delivery requirement to the terminal ileum/colon?
The formulation must deliver 85% to 90% of mesalamine to the terminal ileum and colon.
5) What does the patent say about antacids?
The granulated mesalamine formulation is not administered with antacids (claim 1 and claim 16).
References
[1] US Patent 8,865,688 (claims provided in the prompt text).
